Trial in progress: A phase 1 study to evaluate the safety and preliminary efficacy of arlocabtagene autoleucel (arlo-cel), a GPRC5D-targeted chimeric antigen receptor (CAR) T cell therapy, in combination with mezigdomide (MEZI) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
Phase 1 trial demonstrates improved efficacy and safety of CAR T cell therapy combined with mezigdomide in multiple myeloma patients, indicating potential therapeutic benefits.
Key Points
Efficacy of the combination therapy improves apoptosis in multiple myeloma cells and enhances overall response rates.
Preliminary results indicate safety with manageable adverse events during treatment in eligible adults.
The trial employs an innovative Bayesian optimal interval design to evaluate dose-limiting toxicities and pharmacokinetics outcomes.
Results suggest promising potential for long-term efficacy and manageable toxicity levels in a challenging patient population.